{"id":"raltegravir-use-ral-as-a-simplification-strategy","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Breastfeeding (mother)","Disorder of muscle","Rhabdomyolysis"],"specialPopulations":{}},"trials":[],"_chembl":{"chemblId":"CHEMBL254316","moleculeType":"Small molecule","molecularWeight":"444.42"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Raltegravir (Use RAL as a simplification strategy)","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:10:08.067232+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:10:13.698197+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raltegravir (Use RAL as a simplification strategy)","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:10:14.029277+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL254316/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:15.270495+00:00"}},"offLabel":[],"timeline":[{"date":"2007-10-12","type":"Approval","milestone":"First approval outside the US","regulator":"EMA"}],"_dailymed":null,"aiSummary":"Raltegravir (RAL) is an antiretroviral medication developed by Merck and used primarily for the treatment of HIV infection. It works by inhibiting the integrase enzyme, preventing the virus from integrating its genetic material into the host cell's DNA. RAL is part of the integrase inhibitors class and is typically used in combination with other antiretrovirals. Despite its efficacy, RAL has several side effects, including nausea, headache, and diarrhea. The drug is not approved by the FDA but is used in clinical settings, particularly at Hospital Carlos III in Madrid.","ecosystem":[],"mechanism":{"target":"C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase","novelty":"First-in-class integrase inhibitor","modality":"Small molecule","drugClass":"Integrase inhibitors","explanation":"","oneSentence":"","technicalDetail":"Raltegravir binds to the active site of the HIV integrase enzyme, forming a stable complex that inhibits the strand transfer reaction necessary for viral DNA integration."},"_scrapedAt":"2026-03-28T00:03:40.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":null,"launchDate":null,"annualCostUS":null,"currentRevenue":null,"patientPopulation":null,"peakSalesEstimate":null},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:16.927658+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Human immunodeficiency virus infection","diseaseId":"human-immunodeficiency-virus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":["HIV-1 infection"]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00941083","phase":"PHASE4","title":"Simplification From Protease Inhibitors to Raltegravir","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2009-01","conditions":"HIV Infections","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL254316"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Raltegravir (Use RAL as a simplification strategy)","genericName":"Raltegravir (Use RAL as a simplification strategy)","companyName":"Hospital Carlos III, Madrid","companyId":"hospital-carlos-iii-madrid","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:16.927658+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}